Skip to main content
Premium Trial:

Request an Annual Quote

Evolution of Drug Discovery Process Prompts Society for Biomolecular Screening to Change Name

NEW YORK, Sept. 20 (GenomeWeb News) - The Society for Biomolecular Screening has changed its name to the Society for Biomolecular Sciences, and will now support such areas as ADME-Tox and target discovery, SBS said today.

 

The 11-year-old nonprofit organization decided to make the change following a vote of the membership.

 

"The name change reflects the evolution of a more integrated drug discovery process," Al Kolb, president of SBS, said in a statement.

 

"The society will continue to support traditional screening sciences," Kolb said. "In addition to this core discipline, SBS will reach out to other areas of drug discovery, such as [ADME-Tox] and target discovery, that are becoming more closely linked with high-throughput screening."

 

SBS has more than 2,000 members representing more than 30 countries, 400 companies, and 40 universities. It publishes the Journal of Biomolecular Screening, which will not change its name.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.